A rapid and sensitive UPLC–MS/MS method for determination of remimazolam and its main metabolite in human urine and its application in clinical urine recovery study

• Autorzy: Zhou Y. , Lu M. , Jiang J.

Identyfikatory

DOI

10.1556/1326.2017.00258

• Języki publikacji: EN

Abstrakty

EN

Remimazolam is a new chemical entity belonging to the benzodiazepine class of sedative drugs. A sensitive and rapid method based on ultra-performance liquid chromatography–tandem mass spectrometry (UPLC–MS/MS) has been developed and validated for the determination of remimazolam and its major carboxylic acid metabolite (M1) in human urine. Urine samples were prepared by dilution and analyzed using an isocratic chromatographic separation. Inter- and intra-batch results for remimazolam were within 10.7% for accuracy and 5.5% for precision, and for M1, within 5.8% for accuracy and 4.2% for precision, respectively. This study represents the first reported example for the quantification of remimazolam and its main metabolite in human urine. Furthermore, this method has been successfully applied for the urine recovery study of remimazolam in Chinese healthy subjects. Only about 0.01% of the administered remimazolam dose was eliminated in the urine over the 24 h period in the form of unchanged remimazolam, and more than 75.1% of the administered dose was eliminated in the form of M1. Remimazolam is excreted mainly in the form of M1 in urine after intravenous administration, and there is no excessive accumulation in vivo after administration of remimazolam.

Słowa kluczowe

EN

Remimazolam; metabolite; UPLC–MS/MS; urine recovery study; analytical method

• Wydawca: University of Silesia in Katowice ; Akademiai Kiado
• Czasopismo: Acta Chromatographica
• Rocznik: 2018
• Tom: Vol. 30, no. 2
• Strony: 109--113
• Opis fizyczny: Bibliogr. 10 poz., rys.

Twórcy

autor

Zhou Y.

• Department of Pharmacy The First Affiliated Hospital of Nanchang University, Nanchang 330006, China

autor

Lu M.

• Clinical Pharmacology Research Center, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100730, China

autor

Jiang J.

• Clinical Pharmacology Research Center, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100730, China

Bibliografia

• [1] Kilpatrick, G. J. ; Mclntyre, M. S. ; Cox, R. F. ; Stafford, J. A. ; Pacofsky, G. J. ; Lovell, G. G. ; . Anesthesiology 2007, 1, 60.
• [2] Rogers, W. K. ; McDowell, T. S. IDrugs 2010, 12, 929.
• [3] Upton, R. N. ; Somogyi, A. A. ; Martinez, A. M. ; Colvill, J. ; Grant, C. Br J Anaesth 2010, 6, 798.
• [4] Zhou, Y. ; Wang, H. ; Jiang, J. ; Hu, P. J Chromatogr B Analyt Technol Biomed Life Sci 2015, 976–977, 78.
• [5] US FDA , Guidance for Industry Bioanalytical Method Validation, 2013, www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm368107.pdf, Accessed 22 Aug 2016.
• [6] China Food and Drug Administration , Guideline on clinical pharmacokinetic study of drugs, 2005, www.sfda.gov.cn/directory/web/WS01/images/u6Rp9KpzuB2bSy0qm0+ravwabRp9HQvr+8vMr11ri1vNSt1PIucGRm.pdf, Accessed 22 Aug 2016.
• [7] Taylor, P. J. Clin Biochem 2005, 38, 328.
• [8] Matuszewski, B. K. ; Constanzer, M. L. ; Chavez-Eng, C. M. Anal Chem 2003, 75, 3019.
• [9] Matuszewski, B. K. J Chromatogr B Analyt Technol Biomed Life Sci 2006, 830, 293.
• [10] Zhou, Y. , Hu, P. , Jiang, J. J Pharm Biomed Anal 2017, 137, 78.

Uwagi

PL

Opracowanie rekordu w ramach umowy 509/P-DUN/2018 ze środków MNiSW przeznaczonych na działalność upowszechniającą naukę (2018).